Seeking Young Scientists for Research in Space
Sounds of Science Podcasts
Tackling the Inevitability of Resistance One Genome at a Time
Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
2nd Opinion Genetic Testing
The conflict between genetic diagnostic test makers eager to recoup development costs through patent protection and patient groups seeking broader access to the tests resurfaced during the first of two hearings required by the patent law overhaul enacted in September. The hearing was held by the U.S. Patent and Trademark Office (USPTO) and is required to study how to ensure availability of confirming genetic diagnostic tests where gene patents and exclusive licensing for such tests exist. The final report is due June 16. Industry advocates oppose government efforts to force them to ensure independent second opinion genetic diagnostic testing, calling that an unlawful infringement of their patents. Patient advocates oppose the patenting of genes and genetic diagnostic tests, saying the resulting patent monopolies harm patients.